A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

September 12, 2026

Study Completion Date

September 25, 2026

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG

NNC0194-0499

Participants will receive subcutaneous NNC0194-0499 once weekly.

DRUG

Placebo

Participants will receive placebo matched to NNC0194-0499 subcutaneously.

DRUG

Semaglutide

Participants will receive subcutaneous semaglutide once weekly.

Trial Locations (1)

RECRUITING

Profil Institut für Stoffwechselforschung GmbH, Neuss